Related Experiment Videos
Axillary lymph node dissection: does it have a role in primary breast cancer?
1U. S. Army Medical Corps, Dwight David Eisenhower Army Medical Center, Fort Gordon, Georgia 30905, USA.
The American Surgeon
|February 1, 1996
Summary
Axillary lymph node dissection is valuable in early breast cancer treatment. Positive nodes significantly influence subsequent therapy decisions, supporting its therapeutic benefit.
Area of Science:
- Oncology
- Surgical Oncology
- Breast Cancer Research
Background:
- The necessity of elective lymph node dissection in primary breast cancer treatment is under scrutiny.
- Early breast cancer management requires careful consideration of axillary staging.
Purpose of the Study:
- To evaluate the clinical value of axillary lymph node dissection (ALND) in early-stage breast cancer.
- To determine if axillary node status impacts subsequent treatment strategies.
Main Methods:
- Retrospective review of breast cancer cases treated at Eisenhower Army Medical Center.
- Analysis of 434 breast cancer patients, focusing on 86 with lesions ≤2.0 cm.
- Examination of treatment decisions based on axillary lymph node dissection results.
Main Results:
- Of 81 patients undergoing ALND, 28% had positive axillary nodes.
- Node positivity was 19% for lesions ≤1.0 cm and 35% for lesions 1.1-2.0 cm.
- Positive nodes led to additional therapy in 92% of cases, versus 60% for negative nodes.
Conclusions:
- Axillary lymph node dissection plays a crucial role in determining further treatment for early breast cancer.
- The high incidence of positive nodes (28%) in early-stage disease supports the therapeutic utility of ALND.